Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study

ConditionVitiligo
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-60
SponsorYohanes Firmansyah, dr, MH, MM

About this trial

The goal of this clinical trial is to analyze the effectiveness of SM-hUCMSC secretome administered via microneedling and intradermal microinjection as adjuvant therapy to NB-UVB, compared with NB-UVB alone, in terms of repigmentation, onset of improvement, safety, patient satisfaction, and vitiligo recurrence. The main questions it aims to answer are:

* Are there differences in the level of vitiligo lesion repigmentation among the secretome therapy via microneedling, intradermal microinjection, and NB-UVB phototherapy groups? * Are there differences in the time to onset of repigmentation among the treatment groups? What are the safety profiles and adverse events associated with each treatment modality? * Are there differences in patient satisfaction and quality of life after undergoing each therapy? * Are there differences in vitiligo recurrence rates during the follow-up period among the treatment groups?

Participants will be allocated into three groups as follows:

* Group A receives NB-UVB combined with microneedling and topical 10% secretome. * Group B receives NB-UVB combined with intradermal secretome injection. * Group C receives NB-UVB alone. The intervention period lasts 12 weeks, with follow-up until week 24.

Eligibility criteria

Qualifiers

Patients with a diagnosis of non-segmental vitiligo (established by a dermatologist).

Age 18-60 years.

Fitzpatrick skin types III-V.

Stable vitiligo lesions for at least 6 months (no new lesions and no lesion expansion >10% of body surface area within the past 6 months).

Disqualifiers

Segmental, universal, or other vitiligo types that are difficult to standardize (e.g., lesions limited to the genital area).

Systemic immunomodulatory or immunosuppressive therapy (e.g., systemic corticosteroids, cyclosporine, methotrexate, JAK inhibitors, etc.).

History of keloid formation or hypertrophic scarring at the treatment sites.

Active infection at the lesion sites (bacterial, viral, or fungal) or other skin diseases that may interfere with pigmentation assessment.

Trial design

Treatments tested in this trial

  • NB-UVB combined with microneedling and topical 10% secretome
  • receives NB-UVB combined with intradermal secretome injection
  • NB-UVB alone

Treatment groups

150 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Yohanes Firmansyah, dr, MH, MM

Lead sponsor

Tarumanagara University

Sponsor institution